Roche’s PD-L1 Phase III Breast Study Will Have Broad Enrollment Criteria
This article was originally published in The Pink Sheet Daily
Executive Summary
Lead investigator for Roche’s MPDL3280A in triple negative breast cancer finds it hard to differentiate members of the PD-1/PD-L1 family.
You may also be interested in...
PD-1 Data Promise More Shake-ups In Melanoma Standard of Care
Studies presented at AACR highlight pros and cons of two new potential, competing frontline regimens in melanoma – Keytruda alone instead of Yervoy, or Yervoy in combination with Opdivo.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.